Download PDF
Horm Metab Res 2014; 46(02): 85-93
DOI: 10.1055/s-0033-1354414
Original Basic
© Georg Thieme Verlag KG Stuttgart · New York

Chronic Insulin Exposure does not Cause Insulin Resistance but is Associated with Chemo-resistance in Colon Cancer Cells

I. Baricevic
1   Clinical and Experimental Pharmacology (CEP) Group, Paterson Institute for Cancer Research, Manchester, UK
,
D. L. Roberts
1   Clinical and Experimental Pharmacology (CEP) Group, Paterson Institute for Cancer Research, Manchester, UK
,
A. G. Renehan
1   Clinical and Experimental Pharmacology (CEP) Group, Paterson Institute for Cancer Research, Manchester, UK
2   Faculty Institute of Cancer Sciences, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK
› Author Affiliations
Further Information

Publication History

received 17 April 2013

accepted 12 August 2013

Publication Date:
25 September 2013 (online)

Also available at
    Permissions and Reprints

Abstract

Insulin resistance is an adaptive process in insulin-sensitive tissues characterised by reduced insulin receptor (IR) and insulin-receptor substrate (IRS)-1 expression, increased IRS-1 serine phosphorylation and attenuated downstream signalling. We tested whether this molecular phenotype prevails in cancer cells after long-term exposure to insulin. We characterised expression of IR-related molecules, IRS-1 phosphorylation and downstream signalling in a panel of 5 colon cancer cell lines at different insulin exposures: 15 min (100 nM), approximating to acute stimulation; 48 h (100 nM), used to demonstrate adaptive changes; and 12 weeks (20 nM; chronic insulin exposure, CIE), approximating to chronic hyperinsulinaemia. To assess clinical relevance, we determined IC50 values (increased indicating chemo-resistance) in the CIE-treated cells using oxaliplatin, SN38 (irinotecan) and 5-fluorouracil (5-FU). All colon cancer cell lines (HCT 116, HT-29, C32, CaCo2, LoVo) were sensitive to 15 min insulin exposure with increased phosphorylation of Akt, PRAS40 and p70-S6K. At 48 h, there was incomplete or absent features of insulin resistance. In CIE-treated cells, there was reduced IR expression, incomplete IRS-1 adaptation, lack of signalling pathway attenuation and contra-adaptive increases in IRS-1 tyrosine phosphorylation in several cell types. In CIE cells, there were multiple examples of increased IC50 values (2- to 100-fold) following 24-h treatment with oxaliplatin and SN38, but not with 5-FU. We concluded that CIE in colon cancer cells does not completely induce an insulin resistance molecular phenotype but is associated with chemo-resistance. Adaptive changes seen in insulin-sensitive non-neoplastic cells in response to long-term insulin may not extrapolate to neoplastic cells.

Key words

insulin resistance - insulin receptor - insulin receptor substrate - colon cancer - chemo-resistance

Supporting Information

 

  • References

  • 1 Renehan A, Tyson M, Egger M, Heller RF, Zwahlen M. Body mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371: 569-578
    CrossrefPubMedGoogle Scholar
  • 2 Hursting SD. Minireview: the year in obesity and cancer. Mol Endocrinol 2012; 26: 1961-1966
    CrossrefPubMedGoogle Scholar
  • 3 Inoue M, Tsugane S. Insulin resistance and cancer: epidemiological evidence. Endocr Relat Cancer 2012; 19: F1-F8
    CrossrefPubMedGoogle Scholar
  • 4 Campbell PT, Newton CC, Dehal AN, Jacobs EJ, Patel AV, Gapstur SM. Impact of body mass index on survival after colorectal cancer diagnosis: the Cancer Prevention Study-II Nutrition Cohort. J Clin Oncol 2012; 30: 42-52
    CrossrefPubMedGoogle Scholar
  • 5 Sinicrope FA, Foster NR, Yothers G, Benson A, Seitz JF, Labianca R, Goldberg RM, Degramont A, O’Connell MJ, Sargent DJ. Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. Cancer 2013; 119: 1528-1536
    CrossrefPubMedGoogle Scholar
  • 6 Wolpin BM, Meyerhardt JA, Chan AT, Ng K, Chan JA, Wu K, Pollak MN, Giovannucci EL, Fuchs CS. Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol 2009; 27: 176-185
    CrossrefPubMedGoogle Scholar
  • 7 Smith U, Gale EA. Does diabetes therapy influence the risk of cancer?. Diabetologia 2009; 52: 1699-1708
    CrossrefPubMedGoogle Scholar
  • 8 Varewijck AJ, Janssen JA. Insulin and its analogues and their affinities for the IGF1 receptor. Endocr Relat Cancer 2012; 19: F63-F75
    CrossrefPubMedGoogle Scholar
  • 9 Cohen DH, LeRoith D. Obesity, type 2 diabetes, and cancer: the insulin and IGF connection. Endocr Relat Cancer 2012; 19: F27-F45
    CrossrefPubMedGoogle Scholar
  • 10 Cohen P. The twentieth century struggle to decipher insulin signalling. Nat Rev Mol Cell Biol 2006; 7: 867-873
    CrossrefPubMedGoogle Scholar
  • 11 Copps KD, White MF. Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2. Diabetologia 2012; 55: 2565-2582
    CrossrefPubMedGoogle Scholar
  • 12 Huang XF, Chen JZ. Obesity, the PI3K/Akt signal pathway and colon cancer. Obes Rev 2009; 10: 610-616
    CrossrefPubMedGoogle Scholar
  • 13 Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674
    CrossrefPubMedGoogle Scholar
  • 14 Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12: 21-35
    CrossrefPubMedGoogle Scholar
  • 15 Myers Jr MG, Sun XJ, Cheatham B, Jachna BR, Glasheen EM, Backer JM, White MF. IRS-1 is a common element in insulin and insulin-like growth factor-I signaling to the phosphatidylinositol 3′-kinase. Endocrinology 1993; 132: 1421-1430
    CrossrefPubMedGoogle Scholar
  • 16 Sun XJ, Miralpeix M, Myers Jr MG, Glasheen EM, Backer JM, Kahn CR, White MF. Expression and function of IRS-1 in insulin signal transmission. J Biol Chem 1992; 267: 22662-22672
    PubMedGoogle Scholar
  • 17 Wang LM, Myers Jr MG, Sun XJ, Aaronson SA, White M, Pierce JH. IRS-1: essential for insulin- and IL-4-stimulated mitogenesis in hematopoietic cells. Science 1993; 261: 1591-1594
    CrossrefPubMedGoogle Scholar
  • 18 Bertacca A, Ciccarone A, Cecchetti P, Vianello B, Laurenza I, Del Prato S, Benzi L. High insulin levels impair intracellular receptor trafficking in human cultured myoblasts. Diabetes Res Clin Pract 2007; 78: 316-323
    CrossrefPubMedGoogle Scholar
  • 19 Sasaoka T, Wada T, Ishihara H, Takata Y, Haruta T, Usui I, Ishiki M, Kobayashi M. Synergistic role of the phosphatidylinositol 3-kinase and mitogen-activated protein kinase cascade in the regulation of insulin receptor trafficking. Endocrinology 1999; 140: 3826-3834
    CrossrefPubMedGoogle Scholar
  • 20 Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N. Colorectal cancer. Lancet 2010; 375: 1030-1047
    CrossrefPubMedGoogle Scholar
  • 21 Fischel JL, Rostagno P, Formento P, Dubreuil A, Etienne MC, Milano G. Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines. Br J Cancer 2001; 84: 579-585
    CrossrefPubMedGoogle Scholar
  • 22 Gual P, Le Marchand-Brustel Y, Tanti JF. Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie 2005; 87: 99-109
    CrossrefPubMedGoogle Scholar
  • 23 Dallas NA, Xia L, Fan F, Gray MJ, Gaur P, van Buren 2nd G, Samuel S, Kim MP, Lim SJ, Ellis LM. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 2009; 69: 1951-1957
    CrossrefPubMedGoogle Scholar
  • 24 Seth R, Crook S, Ibrahem S, Fadhil W, Jackson D, Ilyas M. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer. Gut 2009; 58: 1234-1241
    CrossrefPubMedGoogle Scholar
  • 25 Pierre-Eugene C, Pagesy P, Nguyen TT, Neuille M, Tschank G, Tennagels N, Hampe C, Issad T. Effect of insulin analogues on insulin/IGF1 hybrid receptors: increased activation by glargine but not by its metabolites M1 and M2. PLoS One 2012; 7: e41992
    CrossrefPubMedGoogle Scholar
  • 26 Renehan AG, Dive C. Obesity, insulin and chemoresistance in colon cancer. J Gastrointest Oncol 2011; 2: 8-10
    PubMedGoogle Scholar
  • 27 Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006; 1: 1112-1116
    CrossrefPubMedGoogle Scholar
  • 28 Wood IS, De Heredia FP, Wang B, Trayhurn P. Cellular hypoxia and adipose tissue dysfunction in obesity. Proc Nutr Soc 2009; 68: 370-377
    CrossrefPubMedGoogle Scholar
  • 29 Kang SG, Brown AL, Chung JH. Oxygen tension regulates the stability of insulin receptor substrate-1 (IRS-1) through caspase-mediated cleavage. J Biol Chem 2007; 282: 6090-6097
    CrossrefPubMedGoogle Scholar
  • 30 Roberts DL, Williams KJ, Cowen RL, Barathova M, Eustace AJ, Brittain-Dissont S, Tilby MJ, Pearson DG, Ottley CJ, Stratford IJ, Dive C. Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells. Br J Cancer 2009; 101: 1290-1297
    CrossrefPubMedGoogle Scholar
  • 31 Roberts DL, Dive C, Renehan AG. Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med 2010; 61: 301-316
    CrossrefPubMedGoogle Scholar
  • 32 Clayton PE, Banerjee I, Murray PG, Renehan AG. Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. Nature reviews Endocrinology 2011; 7: 11-24
    CrossrefPubMedGoogle Scholar
  • 33 Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab 2006; 17: 328-336
    PubMedGoogle Scholar
  • 34 Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004; 4: 579-591
    CrossrefPubMedGoogle Scholar
  • 35 Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H, Karin M. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010; 140: 197-208
    CrossrefPubMedGoogle Scholar
  • 36 Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8: 915-928
    CrossrefPubMedGoogle Scholar
  • 37 Belfiore A, Malaguarnera R. Insulin receptor and cancer. Endocr Relat Cancer 2011; 18: R125-R147
    CrossrefPubMedGoogle Scholar
  • 38 Ulanet DB, Ludwig DL, Kahn CR, Hanahan D. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci USA 2010; 107: 10791-10798
    CrossrefPubMedGoogle Scholar
  • 39 Dearth RK, Cui X, Kim HJ, Kuiatse I, Lawrence NA, Zhang X, Divisova J, Britton OL, Mohsin S, Allred DC, Hadsell DL, Lee AV. Mammary tumorigenesis and metastasis caused by overexpression of insulin receptor substrate 1 (IRS-1) or IRS-2. Mol Cell Biol 2006; 26: 9302-9314
    CrossrefPubMedGoogle Scholar
  • 40 Bilanges B, Vanhaesebroeck B. A new tool to dissect the function of p70 S6 kinase. Biochem J 2010; 431: e1-e3
    CrossrefPubMedGoogle Scholar
  • 41 Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M, Fumagalli S, Allegrini PR, Kozma SC, Auwerx J, Thomas G. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 2004; 431: 200-205
    CrossrefPubMedGoogle Scholar
  • 42 Tremblay F, Brule S, Hee Um S, Li Y, Masuda K, Roden M, Sun XJ, Krebs M, Polakiewicz RD, Thomas G, Marette A. Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance. Proc Natl Acad Sci USA 2007; 104: 14056-14061
    CrossrefPubMedGoogle Scholar
  • 43 Hansen BF. Insulin analogues with increased mitogenic potency – are they safe?. Horm Metab Res 2008; 40: 431-433
    Article in Thieme ConnectPubMedGoogle Scholar